Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24500908 | 1.00 | GRIA1 (0.54) | GRIA1GRIA4KDM1ANPY5RGRIA2 | |
| SCHEMBL8393459 | 0.92 | GRIA1 (0.50) | GRIA1GRIA4KDM1A | |
| SCHEMBL6564728 | 0.88 | GRIA1 (0.61) | GRIA1GRIA4KDM1ANPY5R | |
| SCHEMBL7469496 | 0.86 | GRIA1 (0.44) | GRIA1GRIA4KDM1ANPY5RGRIA2 | |
| SCHEMBL8395807 | 0.81 | GRIA1 (0.57) | GRIA1GRIA4KDM1A | |
| SCHEMBL7472680 | 0.81 | GRIA1 (0.40) | GRIA1GRIA4 | |
| SCHEMBL18624727 | 0.78 | GRIA1 (0.46) | GRIA1NPY5R | |
| SCHEMBL13610004 | 0.77 | GRIA1 (0.75) | GRIA1GRIA4NPY5RGRIA2GRIA3 | |
| SCHEMBL8396887 | 0.76 | SIRT2 (0.38) | KDM1A | |
| SCHEMBL13907076 | 0.72 | NPY5R (0.41) | GRIA1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | GRIA1 9/4885GRIA4 17/4885KDM1A 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.